Table 1.
Basic characteristics of International Warfarin Pharmacogenetics Consortium patients included in this study.
Table 2.
Mean absolute error and percentage within 20% of actual dose in validation cohorts.
Data are expressed as mean (95% CI) or percentage.MAE: mean absolute error; MLR: multiple linear regression; SVR: support vector regression; ANN: artificial neural network; RT: regression tree; RFR: random forest regression; BRT: boosted regression tree; MARS: multivariate adaptive regression splines; LAR: lasso regression; BART: Bayesian additive regression trees. To build warfarin dose algorithms in the whole training cohort, the covariates were race, genotypes of VKORC1 and CYP2C9, age in years, weight in kg, height in cm, smoking history, amiodarone use, and enzyme inducer use; in the Asian cohort, the covariates were genotypes of VKORC1 and CYP2C9, age in years, weight in kg, amiodarone use, and smoking history; in the White and Black cohorts, the covariates were genotypes of VKORC1 and CYP2C9, age in years, weight in kg, amiodarone use, smoking history, and enzyme inducer use.
Table 3.
Mean absolute error and mean percentage within 20% of actual dose by the therapeutic warfarin dose range in the validation cohort.
Data are expressed as mean (95% CI) or percentage.MAE: mean absolute error; MLR: multiple linear regression; SVR: support vector regression; ANN: artificial neural network; RT: regression tree; RFR: random forest regression; BRT: boosted regression tree; MARS: multivariate adaptive regression splines; LAR: lasso regression; BART: Bayesian additive regression trees. The warfarin dose range was divided into three categories based on the 25% and 75% quantiles of WSD in terms of race: in the Asian population: low dose (≤ 14 mg/week), intermediate dose (14–26.25 mg/week), and high dose (> 26.25 mg/week); in the White cohort: low dose (≤22 mg/week), intermediate dose (22–42.49 mg/week), and high dose (>42.49 mg/week); in the Black cohort: low dose (≤30 mg/week), intermediate dose (30–52.5 mg/week), and high dose (>52.5 mg/week); and in the missing or mixed race: low dose (≤22.5 mg/week), intermediate dose (22.5–40 mg/week), and high-dose (>40 mg/week).